Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 887-900

  Beuselinck, B ^a,b   Karadimou, A ^b   Lambrechts, D ^c,d   Claes, B ^a   Wolter, P ^b   Couchy, G ^a   Berkers, J ^a   Paridaens, R ^a   Schoffski P ^a   Mejean A ^e   Verkarre, V ^f   Lerut, E ^a   De La Taille, A ^g   Tourani, J M ^h   Bigot, P ⁱ   Linassier, C ^j   Negrier S ^k   Berger, J ^l   Patard, J J ^m   Zucman Rossi, J ^b,e   Oudard, S ^b,e   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSERM   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITÉ DE POITIERS   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF TOURS   (France)

^k Lé on Bé rard Center   (France)

^l DUPUYTREN UNIVERSITY HOSPITAL   (France)

^m BICÊTRE HOSPITAL   (France)

more..

Author keywords

outcome; renal cell carcinoma; single nucleotide polymorphisms; sunitinib

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER SURVIVAL; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875168504     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.548     Document Type: Article

References (20)

1. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear cell renal cell carcinoma treated with Sunitinib. Ann Oncol 22: 794-800.
2. Dietrich CG, Geier A, Oude Elferink RPJ (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795.
3. Garcia-Donas J, Esteban E, Leandro-Garc?a LJ, Castellano DE, Del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Mart?nez E, Moreno F, Font A, Robledo M, Rodr?guez-Antona C (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with firstline sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
4. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27: 235-241.
5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.
6. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66: 357-371.
7. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA (2008) Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 5: e108.
8. Motzer R, Bacik J, Mazumbar M (2004) Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience. Clin Cancer Res 10: 6202S-6203S.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
11. Partanen TA, Alitalo K, Miettinen M (1999) Lack of lymphatic vascular specificity of vascular endothelial growth factor 3 in 185 vascular tumors. Cancer 86: 2406-2412.
12. Patil S, Figlin R, Hutson T, Michaelson M, Negrier S, Kim T, Huang X, Motzer R (2011) Prognostic factors for progression free survival and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22: 295-300.
13. Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, Van Loo P, Van Den Bossche M, Catthoor K, Sabbe B, Despierre E, Vergote I, Hilbush B, Lambrechts D, Del-Favero J (2011) Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol 30: 61-68.
14. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
15. Soto-Vega E, Arroyo C, Richaud-Patin Y, Garcia-Carrasco M, Vazquez-Lavista LG, Llorente L (2009) P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 27: 363-366.
16. Valtola R, Salven P, Heikkil P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390.
17. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA (2010) Genetic polymorphisms associated with a prolonged progressionfree survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17: 620-629.
18. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O'Driscoll L (2009) Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 9: 6.
19. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon LR, Mooser VE, Pandite LN (2011a) Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesisrelated and exposure-related genes. J Clin Oncol 29: 2557-2564.
20. Xu CF, Ball HA, Bing N, Sternberg C, Xue Z, McCann L, King K, Spraggs C, Mooser V, Pandite LN (2011b) Association of genetic markers in angiogenesisor exposure-related genes with overall survival in pazopanib-treated patients with advanced renal cell carcinoma. J Clin Oncol 29(Suppl 7): abstr 303.